Back to top
more

Owens & Minor (OMI)

(Delayed Data from NYSE)

$14.58 USD

14.58
372,349

-0.20 (-1.35%)

Updated Oct 3, 2024 04:00 PM ET

After-Market: $14.58 0.00 (0.00%) 4:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (49 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Technology (ALGN) Q1 Earnings Beat Estimates, Margins Up

by Zacks Equity Research

Align Technology's (ALGN) segments report solid Q1 sales across geographies despite the pandemic-led business challenges.

Owens & Minor (OMI) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Owens & Minor (OMI) closed at $36.84 in the latest trading session, marking a +0.16% move from the prior day.

Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.

Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues

by Zacks Equity Research

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.

Owens & Minor (OMI) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Owens & Minor (OMI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.

Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up

by Zacks Equity Research

Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.

InMode (INMD) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.

Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) PPE sales from its medical business are likely to have maintained the momentum. Also, global recovery trends of its dental business are expected to aid Q1 results.

Is a Beat in the Cards for CVS Health (CVS) in Q1 Earnings?

by Zacks Equity Research

Given the increasing number of walk-in-clinical appointments and patient visits, CVS Health (CVS), which has a huge PBM client base, is expected to have seen a sequential rebound in Q1 revenues.

Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) first-quarter 2021 revenues are likely to have been adversely impacted due to pandemic-led lower elective procedure volumes.

Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.

What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?

by Zacks Equity Research

IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.

Thermo Fisher (TMO) to Report Q1 Earnings: WIll It Beat?

by Zacks Equity Research

Fewer hospital visits on growing new cases might have once again impacted the level of routine diagnostics testing activity for Thermo Fisher (TMO) in Q1.

New Launches in Breast Health to Aid Hologic (HOLX) Q2 Earnings

by Zacks Equity Research

Strength in Molecular Diagnostics business is likely to have continued to aid Hologic's (HOLX) performance in the second quarter of fiscal 2021.

Hologic (HOLX) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Hologic (HOLX) is likely to have gained during fiscal second-quarter 2021 on the back of robust performances of its business arms despite coronavirus-led economic doldrums.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Owens & Minor (OMI) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Owens & Minor (OMI) closed at $38.18, marking a +0.77% move from the previous day.

Top Ranked Growth Stocks to Buy for April 22nd

by Zacks Equity Research

BSET, OMI, and BCC made it to the Zacks Rank #1 (Strong Buy) growth stocks list on April 22, 2021

Align Technology (ALGN) to Post Q1 Earnings: What's in Store?

by Zacks Equity Research

Align Technology (ALGN) is expected to have gained from robust Invisalign aligners and iTero scanners shipment volume in Q1.

Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong

by Zacks Equity Research

The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.

Kinjel Shah headshot

Enhance Your Portfolio With These 6 Low Price-to-Book Stocks

by Kinjel Shah

P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects

Illumina (ILMN) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

Illumina (ILMN) is likely to have gained during the first quarter on the back of robust performance of the sequencing consumable segment.

Sumit Singh headshot

Unlock the Value of Your Portfolio With 4 Low P/CF Stocks

by Sumit Singh

Value investing is essentially about selecting stocks that are usually cheap but fundamentally sound. Goldman Sachs (GS), Owens & Minor (OMI), Boise Cascade (BCC) and Vishay Intertechnology (VSH) boast low P/CF ratio.

Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences

by Zacks Equity Research

Zacks Industry Outlook Highlights: MedTech, including Natus Medical, Owens & Minor, Penumbra, Apollo Medical and ENDRA Life Sciences